Trial Profile
A multicenter, double-blind, randomized, parallel, placebo-controlled study to examine the efficacy of rizatriptan 10 Mg tablet administered early during a migraine attack while the pain is mild
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Rizatriptan (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAME-1
- Sponsors Organon
- 12 May 2009 Trial identifier (MK0462-066) identified as reported by ClinicalTrials.gov.
- 01 Oct 2005 New trial record.